Browse News
Filter News
Found 43 articles
-
Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
6/1/2023
Alkermes plc announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc, the new independent public company to be established upon the planned separation of Alkermes' oncology business.
-
American Liver Foundation Hosts the 31st Annual Irwin M. Arias Symposium
11/3/2022
The American Liver Foundation is pleased to host its 31st annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease, on November 10th from 9AM to 5PM ET.
-
Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022
10/25/2022
Glympse today announced that it will present a poster demonstrating that its novel protease biosensor diagnostic platform can detect hepatocellular carcinoma (HCC) at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2022, being held in Washington, D.C., from Nov. 4-8, 2022.
-
With the appointment of new CEOs, CMOs and CSOs, biopharma and life sciences organizations shuffled their leadership positions as Q3 comes to a close.
-
ImmuneID Appoints Jessica Atkinson as Chief Business Officer
10/17/2022
ImmuneID today announced the appointment of Jessica Atkinson as Chief Business Officer, where she will oversee business activities as part of ImmuneID leadership with dual goals of advising on the company's current direction and exploring and maximizing external collaboration opportunities for its aiSPIRE platform.
-
Glympse to Present Two Posters Demonstrating Novel Protease Biosensor Diagnostic Platform Detection of Hepatocellular Carcinoma at EASL ILC 2022
6/8/2022
Glympse to Present Two Posters Demonstrating Novel Protease Biosensor Diagnostic Platform Detection of Hepatocellular Carcinoma at EASL ILC 2022.
-
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Glympse Appoints Jonathan Wilde, Ph.D., as Chief Scientific Officer to Advance Biosensor Assay Platform
5/17/2022
Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, announced the appointment of Jonathan Wilde, Ph.D., as Chief Scientific Officer.
-
72% of employers are currently experiencing a decrease in the volume of candidates applying to their jobs.
-
This liquid biopsy uses a panel of peptide biosensors to analyze protein activity from a blood sample and provide actionable readouts of the disease state.
-
Glympse to Present Dataset Demonstrating Liquid Biopsy Approach to Predict NASH at AASLD's The Liver Meeting
11/12/2021
Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, today announced new details about its upcoming late breaker oral presentation at the American Association for the Study of Liver Disease (AASLD) annual The Liver Meeting, being held virtually from Nov. 12-15, 2021.
-
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
-
Glympse to Present Data from First Application of New Liquid Biopsy Diagnostic Platform at AASLD's The Liver Meeting 2021
11/1/2021
Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, announced that it will be presenting on the new liquid biopsy approach to its biosensor platform at the American Association for the Study of Liver Disease annual The Liver Meeting, being held virtually from Nov. 12-15, 2021.
-
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
9/14/2021
ROME Therapeutics, a biotechnology company harnessing the power of the repeatome for drug development, announced the completion of a $77 million Series B financing led by new investor Section 32.
-
BioSpace Movers & Shakers, Sept. 10
9/10/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Glympse Appoints Tram Tran, M.D., as Chief Medical Officer
9/8/2021
Glympse, a biotechnology company developing innovative technology to improve disease diagnosis and monitoring, announced the appointment of Tram Tran, M.D., to the newly created role of Chief Medical Officer.
-
BioSpace Movers & Shakers, July 23
7/23/2021
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Glympse Bio Appoints Matthew T. Navarro, J.D., as Chief Financial Officer
7/20/2021
Glympse Bio today announced the appointment of Matthew T. Navarro , J.D., to the newly-created role of Chief Financial Officer.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Glympse Bio Names Jessica Atkinson Senior Vice President of Business Development
2/2/2021
Glympse Bio and pharmaceutical executive brings expertise leading new business initiatives and partnerships